Tilsotolimod

Phase 2Small molecule

AbbVie

Tilsotolimod is one of 84 small molecule programs targeting Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorsActive, not recruiting

MelanomaRecruiting

Solid TumorsPhase 2

Active, not recruiting

MelanomaPhase 2

Recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Cotellic

21 4

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 5

Taxol

Teva

Phase 3

13 6

Mektovi

Pfizer

Phase 3

12 7

Tecentriq

Roche

Phase 3

11 8

Lenvima

Eisai

Phase 3

9 9

Libtayo

Regeneron

Phase 3

6 10

Intron a

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Melanoma

NCT04126876

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed· AbbVie logo

AbbVie·Phase 1·NCT04196283·30 enrolled

Melanoma1 trial

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Recruiting·AA.J.M. van den Eertwegh·Phase 2·NCT04126876·214 enrolled

Solid Tumors1 trial

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Active, not recruiting·IIdera Pharmaceuticals, Inc.·Phase 2·NCT03865082·30 enrolled

Advanced Cancers1 trial

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT04270864·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tilsotolimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tilsotolimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tilsotolimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Tilsotolimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Melanoma1 trial

Solid Tumors1 trial

Advanced Cancers1 trial

References

Drug Info

Quick Facts

Related News